There are no plans to meet with the National Institute for Health and Care Excellence (NICE) to discuss its technology appraisal guidance on Orkambi (lumacaftor-ivacaftor) for treating cystic fibrosis homozygous for the F508del mutation. NICE is the independent body which makes decisions on the clinical and cost effectiveness of products based on thorough assessment of the best available evidence. NICE’s guidance is based on a thorough assessment of the available evidence and is developed through wide consultation with stakeholders.